NCT00517790

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.

Conditions

• Non-Small Cell Lung Cancer (NSCLC)

Interventions

Type	Name	Description
DRUG	ABT-869 .25 mg/kg	Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
DRUG	ABT-869 0.10 mg/kg	Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.

Timeline

• Start date: 2007-08-01
• Primary completion: 2011-06-01
• Completion: 2012-06-01
• First posted: 2007-08-17
• Last updated: 2013-04-05

Locations

28 sites across 5 countries: United States, Canada, France, Singapore, Taiwan